Hypersensitivity reaction studies of a polyethoxylated castor oil-free, liposome-based alternative paclitaxel formulation

Molecular Medicine Reports

Volumn 7, Issue 3, 2013, Pages 947-952

  Wang, Hongbo ^a   Cheng, Guang ^b   Du, Yuan ^a   Ye, Liang ^c   Chen, Wenzhong ^b   Zhang, Leiming ^a   Wang, Tian ^a   Tian, Jingwei ^c   Fu, Fenghua ^a  

^a YANTAI UNIVERSITY   (China)

^b Nanjing Luye Sike Pharmaceutical Co Ltd   (China)

^c Luye Pharma Group Ltd   (China)

Author keywords

Complement activation; Hypersensitivity reaction; Liposome; Lipusu; Taxol

Indexed keywords

CIMETIDINE; COMPLEMENT MEMBRANE ATTACK COMPLEX; DEXAMETHASONE; HISTAMINE; LIPOSOME; LIPUSU; PACLITAXEL; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER CELL CULTURE; CELL ASSAY; COMPLEMENT ACTIVATION; COMPLEMENT BLOOD LEVEL; CORTICOSTEROID THERAPY; DOSE RESPONSE; DRUG CYTOTOXICITY; DRUG DOSE COMPARISON; DRUG FORMULATION; DRUG HYPERSENSITIVITY; DRUG SAFETY; ENZYME LINKED IMMUNOSORBENT ASSAY; HISTAMINE RELEASE; HISTOPATHOLOGY; HUMAN; HUMAN CELL CULTURE; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; LETHAL DOSE; LIPOSOMAL DELIVERY; LUNG EDEMA; MALE; MOUSE; MOUTH CARCINOMA; NONHUMAN; NORMAL HUMAN; SINGLE DRUG DOSE;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CASTOR OIL; CELL LINE, TUMOR; CELL SURVIVAL; CHEMISTRY, PHARMACEUTICAL; COMPLEMENT ACTIVATION; COMPLEMENT MEMBRANE ATTACK COMPLEX; COMPLEMENT SYSTEM PROTEINS; ENZYME-LINKED IMMUNOSORBENT ASSAY; HISTAMINE; HUMANS; HYPERSENSITIVITY; LIPOSOMES; LUNG; MICE; NEOPLASMS; PACLITAXEL;

EID: 84873129048     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2013.1264     Document Type: Article

References (24)

1. Jordan MA and Wilson L: Microtubules as a target for anticancer drugs. Nat Rev Cancer 4:253-265, 2004. (Pubitemid 38525281)
2. Kavallaris M: Microtubules and resistance to tubulin-binding agents. Nat Rev Cancer 10:194-204, 2010.
3. Adams JD, Flora KP, Goldspiel BR, Wilson JW, Arbuck SG and Finley R: Taxol: a history of pharmaceutical development and current pharmaceutical concerns. J Natl Cancer Inst Monogr 141-147, 1993.
4. Szebeni J, Muggia FM and Alving CR: Complement activation by Cremophor EL as a possible contributor to hypersensitivity to paclitaxel: an in vitro study. J Natl Cancer Inst 90:300-306, 1998. (Pubitemid 28182386)
5. Rowinsky EK, Eisenhauer EA, Chaudhry V, Arbuck SG and Donehower RC: Clinical toxicities encountered with paclitaxel (Taxol). Semin Oncol 20:1-15, 1993. (Pubitemid 23239390)
6. Weiszhar Z, Czucz J, Revesz C, Rosivall L, Szebeni J and Rozsnyay Z: Complement activation by polyethoxylated pharmaceutical surfactants: Cremophor-EL, Tween-80 and Tween-20. Eur J Pharm Sci 45:492-498, 2012.
7. Hennenfent KL and Govindan R: Novel formulations of taxanes: a review. Old wine in a new bottle? Ann Oncol 17:735-749, 2006.
8. Koudelka S and Turanek J: Liposomal paclitaxel formulations. J Control Release 163:322-334, 2012.
9. Luo C, Wang Y, Chen Q, et al: Advances of paclitaxel formulations based on nanosystem delivery technology. Mini Rev Med Chem 12:434-444, 2012.
10. Elsadek B and Kratz F: Impact of albumin on drug delivery - new applications on the horizon. J Control Release 157:4-28, 2012.
11. Ribeiro JT, Macedo LT, Curigliano G, et al: Cytotoxic drugs for patients with breast cancer in the era of targeted treatment: back to the future? Ann Oncol 23:547-555, 2012.
12. Ferlini C, Gallo D and Scambia G: New taxanes in development. Expert Opin Investig Drugs 17:335-347, 2008. (Pubitemid 351578186)
13. Porche DJ: Liposomal doxorubicin (Doxil). J Assoc Nurses AIDS Care 7:55-59, 1996.
14. Petrikkos GL: Lipid formulations of amphotericin B as first-line treatment of zygomycosis. Clin Microbiol Infect 15 Suppl 5:87-92, 2009.
15. Zhang JA, Anyarambhatla G, Ma L, et al: Development and characterization of a novel Cremophor EL free liposome-based paclitaxel (LEP-ETU) formulation. Eur J Pharm Biopharm 59:177-187, 2005. (Pubitemid 39573451)
16. Fasol U, Frost A, Buchert M, et al: Vascular and pharmacokinetic effects of EndoTAG-1 in patients with advanced cancer and liver metastasis. Ann Oncol 23:1030-1036, 2012.
17. Rosiello AP, Essignmann JM and Wogan GN: Rapid and accurate determination of the median lethal dose (LD50) and its error with a small computer. J Toxicol Environ Health 3:797-809, 1977. (Pubitemid 8271162)
18. Rose WC: Taxol-based combination chemotherapy and other in vivo preclinical antitumor studies. J Natl Cancer Inst Monogr 47-53, 1993.
19. Wang H, Li H, Zuo M, et al: Lx2-32c, a novel taxane and its antitumor activities in vitro and in vivo. Cancer Lett 268:89-97, 2008.
20. Szebeni J: Complement activation-related pseudoallergy: a new class of drug-induced acute immune toxicity. Toxicology 216:106-121, 2005. (Pubitemid 41712000)
21. Karasuyama H, Tsujimura Y, Obata K and Mukai K: Role for basophils in systemic anaphylaxis. Chem Immunol Allergy 95:85-97, 2010.
22. Bossi F, Fischetti F, Pellis V, et al: Platelet-activating factor and kinin-dependent vascular leakage as a novel functional activity of the soluble terminal complement complex. J Immunol 173:6921-6927, 2004. (Pubitemid 39541080)
23. Cabanes A, Briggs KE, Gokhale PC, Treat JA and Rahman A: Comparative in vivo studies with paclitaxel and liposome-encapsulated paclitaxel. Int J Oncol 12:1035-1040, 1998. (Pubitemid 28186763)
24. Xia XJ, Guo RF, Liu YL, et al: Formulation, characterization and hypersensitivity evaluation of an intravenous emulsion loaded with a paclitaxel-cholesterol complex. Chem Pharm Bull (Tokyo) 59:321-326, 2011.